Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tenecteplase vs Alteplase in Chinese Acute Ischaemic Stroke
NCT04915729Phase 3Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Jun 2021
- Primary completion
- Oct 2023
- Modality
- rProtein (Recombinant Protein), Biologic
- Countries
- 1
01
Overview
A Phase 3 trial of tenecteplase in ischemic stroke, sponsored by Boehringer Ingelheim. Started Jun 2021; status: completed.
02
Drugs
tenecteplase
03
Conditions
ischemic stroke
Beyond the preview
Go deeper on NCT04915729.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04915729.